Jakarta, 29 May 2023 Through our Community-Led Monitoring (CLM) of Viral Hepatitis services, we found that since 2019 there have been several stockouts of Hepatitis C medicines. The most current one is the stock-out of Daclatasvir since early April 2023. Today, Peduli Hati Bangsa together with other community organizations carry out an action to ask…
Tag: hepatitis c
Peduli Hati Bangsa, together with the Clinton Health Access Initiative (CHAI) had the opportunity to have a discussion with the National Narcotics Agency (BNN). We were received by: In 2021 WHO reported that the number of HBV has reached 296 million and HCV around 58 million, with 23-39% of the total new HCV cases being…
From the records of Peduli Hati Bangsa, delays in the procurement of Direct Acting Antiviral (DAA) drugs to treat Hepatitis C have occurred several times: And currently the Daclatasvir stock out occurs from the end of March to August 2023. For patients who have already started, it is certainly not easy because generic drugs are…
Report of the community led monitoring in 2021 as the our base for advocacy to improve HIV and Hepatitis C services this year. Access the report from this link: https://www.amfar.org/treat-asia/cto-analysis-2022/ Thank you AmfAR, The Foundation for AIDS Research for the chance and precious learning process and we hope to push for a better quality of…
On Tuesday-Thursday, May 10-12 2022, screening for Hepatitis C (HCV) and HIV was carried out at the Class IIA Kerobokan Penitentiary (Lapas) and Class IIA Women’s Prison Denpasar (Bali) with a total of 1,326 inmates. The positivity rates for HCV were 2.94% and 2.49% for HIV. All those who are HCV positive will continue with…